The GLP-1R Agonists in the Treatment of Adult, Symptomatic, Obese Asthma (GATA-3) study (ClinicalTrials.gov NCT05254314) is the first randomized, double-blind, placebo-controlled trial designed to evaluate the effect of the glucagon-like peptide 1 (GLP-1) incretin pathway in asthma. Here, GCG is linked to asthma.